Radioisotope therapy in bone and joint disease

Area of Science:

• Nuclear Medicine
• Oncology
• Rheumatology

Background:

• Beta-emitting radioisotopes offer targeted tissue destruction for painful conditions.
• Sodium phosphate P 32 has been used for skeletal metastases, with enhanced uptake via steroids or parathyroid hormone.
• Colloidal preparations, like 198Au, are used for rheumatoid disease, particularly joint effusions.

Purpose of the Study:

• To evaluate the efficacy and safety of beta-emitting radioisotopes for painful metastatic bone disease.
• To explore the use of radiation-induced necrosis for nonmalignant proliferative synovium in rheumatoid disease.
• To assess newer radioisotope agents for improved therapeutic/toxic ratios and reduced side effects.

Main Methods:

• Utilizing beta-emitting radioisotopes (e.g., P 32, 89Sr) for targeted delivery to bone lesions.
• Employing pharmacologic stimulation (androgenic steroids, parathyroid hormone) to increase radioisotope uptake.
• Administering colloidal radioisotopes (e.g., 198Au, 165Dy, 32P) for intra-articular treatment.

Main Results:

• Sodium phosphate P 32 provides high subjective pain relief for skeletal metastases but does not prolong survival and can cause marrow depression.
• 89Sr may offer a better therapeutic/toxic ratio for bone metastases.
• Colloidal preparations provide high symptom relief for rheumatoid disease, especially joint effusions, but do not reverse the underlying disease.

Conclusions:

• Radioisotope therapy is effective for symptomatic relief in bone metastases and rheumatoid disease.
• Further investigation of agents like 89Sr is warranted for bone metastases.
• Safer colloidal agents are being developed to mitigate risks like lymph node leakage and lymphocyte irradiation.